Champix is the trade name of a drug called varenicline launched in the UK in December 2006 as a stop-smoking aid for adults. It is a non-nicotine based medicine designed to help people stop smoking.
Champix can help reduce the cravings and withdrawal symptoms associated with stopping smoking. Also if someone taking Champix smokes a cigarette they may find it less satisfying and less pleasurable than before, which can reduce the risk of a complete relapse. Immediately after treatment, the risk of relapse is increased and some patients experience irritability, depression or insomnia.
A systemic review of published research shows that Champix does increase a smoker’s chance of stopping smoking between two- and three-fold when compared with placebo, also performing slightly better than nicotine replacement patches and bupropion (Zyban).
Champix is available on prescription in Scotland. It was approved by the Scottish Medicines Consortium (SMC) in January 2007: Varenicline (Champix) for smoking cessation and by the National Institute of Clinical Excellence (NICE) in February 2008: NICE guidance.
Champix is not recommended for:
You must not use varenicline without speaking to your doctor if you:
It’s important that you tell your doctor what other medicines you are taking (including those bought without a prescription) before Champix is prescribed for you, and to tell your doctor or pharmacist that you are taking Champix before you take any new medicines.
Information in this section taken from the Medicines and Healthcare products Regulatory Agency - the government agency responsible for ensuring that medicines work, and are safe.
Patients who are taking varenicline who develop suicidal thoughts, agitation, depressed mood, or display any changes in behaviour that are of concern for the patient, family, or caregiver should stop use of varenicline and contact their doctor immediately.
As varenicline is a relativey new drug on the market, information about its use in the general population is limited. Healthcare professionals and patients are encouraged to report any side effects believed to be associated with varenicline use via MHRA's Yellow Card Scheme.
For further information please contact the ASH Scotland Information Service by email at enquiries@ashscotland.org.uk or by phone on 0131 225 4725 (open Monday-Friday during office hours)
For help and advice on stopping smoking please call the NHS Health Scotland Smokeline on 0800 84 84 84 (open daily from noon to midnight) or visit canstopsmoking.com